Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.


Adjuvant systemic therapy for women with node-negative breast cancer is most easily justified for those patients at highest risk of relapse. We have examined the impact of tumor size, histologic grade, estrogen receptor (ER) status, tumor ploidy, and S-phase fraction (SPF) on relapse-free survival (RFS) for 169 patients with node-negative breast cancer in… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.